These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
586 related articles for article (PubMed ID: 23063351)
1. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis. An X; Lin X; Wang FH; Goodman K; Cai PQ; Kong LH; Fang YJ; Gao YH; Lin JZ; Wan DS; Pan ZZ; Ding PR Eur J Cancer; 2013 Mar; 49(4):843-51. PubMed ID: 23063351 [TBL] [Abstract][Full Text] [Related]
2. Fluorouracil-based neoadjuvant chemoradiotherapy with or without oxaliplatin for treatment of locally advanced rectal cancer: An updated systematic review and meta-analysis. Yang YJ; Cao L; Li ZW; Zhao L; Wu HF; Yue D; Yang JL; Zhou ZR; Liu SX Oncotarget; 2016 Jul; 7(29):45513-45524. PubMed ID: 27322422 [TBL] [Abstract][Full Text] [Related]
3. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174 [TBL] [Abstract][Full Text] [Related]
4. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial. Vestermark LW; Jensen HA; Pfeiffer P Acta Oncol; 2012 Mar; 51(3):311-7. PubMed ID: 22248062 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer. Gao YH; An X; Sun WJ; Cai J; Cai MY; Kong LH; Lin JZ; Liu GC; Tang JH; Wu XJ; Chen G; Pan ZZ; Ding PR J Surg Oncol; 2014 Apr; 109(5):478-82. PubMed ID: 24288203 [TBL] [Abstract][Full Text] [Related]
6. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT. Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978 [TBL] [Abstract][Full Text] [Related]
7. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer. Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. Arkenau HT; Arnold D; Cassidy J; Diaz-Rubio E; Douillard JY; Hochster H; Martoni A; Grothey A; Hinke A; Schmiegel W; Schmoll HJ; Porschen R J Clin Oncol; 2008 Dec; 26(36):5910-7. PubMed ID: 19018087 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339 [TBL] [Abstract][Full Text] [Related]
10. T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen. Martijnse IS; Dudink RL; Kusters M; Vermeer TA; West NP; Nieuwenhuijzen GA; van Lijnschoten I; Martijn H; Creemers GJ; Lemmens VE; van de Velde CJ; Sebag-Montefiore D; Glynne-Jones R; Quirke P; Rutten HJ Ann Surg Oncol; 2012 Feb; 19(2):392-401. PubMed ID: 21792506 [TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720 [TBL] [Abstract][Full Text] [Related]
12. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Rödel C; Liersch T; Becker H; Fietkau R; Hohenberger W; Hothorn T; Graeven U; Arnold D; Lang-Welzenbach M; Raab HR; Sülberg H; Wittekind C; Potapov S; Staib L; Hess C; Weigang-Köhler K; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Lancet Oncol; 2012 Jul; 13(7):679-87. PubMed ID: 22627104 [TBL] [Abstract][Full Text] [Related]
13. Analysis of bevacizumab-based preoperative radiochemotherapy in patients with locally advanced rectal cancer on surgery-associated spectrum of complications. Dellas K; Buller J; Görtz GJ; Richter M; Höhler T; Arnold D; Keck T; Dunst J; Zühlke H Ann Surg Oncol; 2014 Apr; 21(4):1352-60. PubMed ID: 24306667 [TBL] [Abstract][Full Text] [Related]
14. Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer -- impact on long-term quality of life. Kripp M; Wieneke J; Kienle P; Welzel G; Brade J; Horisberger K; Wenz F; Post S; Gencer D; Hofmann WK; Hofheinz RD Eur J Surg Oncol; 2012 Jun; 38(6):472-7. PubMed ID: 22349986 [TBL] [Abstract][Full Text] [Related]
15. Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: A meta-analysis of randomized trials comparing surgery ± a fluoropyrimidine and surgery + a fluoropyrimidine ± oxaliplatin. Bujko K; Glimelius B; Valentini V; Michalski W; Spalek M Eur J Surg Oncol; 2015 Jun; 41(6):713-23. PubMed ID: 25911110 [TBL] [Abstract][Full Text] [Related]
16. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial. Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731 [TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of neoadjuvant chemoradiation therapy with oxaliplatin and capecitabine or 5-fluorouracil for locally advanced rectal cancer. Lu JY; Xiao Y; Qiu HZ; Wu B; Lin GL; Xu L; Zhang GN; Hu K J Surg Oncol; 2013 Sep; 108(4):213-9. PubMed ID: 23913795 [TBL] [Abstract][Full Text] [Related]
18. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Velenik V; Ocvirk J; Oblak I; Anderluh F Eur J Surg Oncol; 2010 Mar; 36(3):244-50. PubMed ID: 20042310 [TBL] [Abstract][Full Text] [Related]
19. Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose. Lee SH; Lee KC; Choi JH; Oh JH; Baek JH; Park SH; Shin DB Jpn J Clin Oncol; 2008 Feb; 38(2):112-21. PubMed ID: 18263881 [TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. ; Ryan DP; Niedzwiecki D; Hollis D; Mediema BE; Wadler S; Tepper JE; Goldberg RM; Mayer RJ J Clin Oncol; 2006 Jun; 24(16):2557-62. PubMed ID: 16636336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]